GSK (GSK) Earnings Date & Reports

Key Takeaways

• Revenue beat: GSK posted second-quarter turnover of £8.41 billion, exceeding the analyst consensus of £8.24 billion and rising 5% at constant exchange rates (CER).
• Profit outperformance: Core operating profit reached £2.80 billion, ahead of the £2.68 billion consensus, while core earnings per share (EPS) of 50.5 pence comfortably beat the 47.1 pence forecast.
• Specialty Medicines lead the way: The division grew 14% to £3.8 billion, driven by double-digit gains in Oncology, HIV, and Respiratory, Immunology & Inflammation.
• Vaccines momentum continues: Sales rose 8% to £2.3 billion, with Arexvy more than doubling and Shingrix delivering £888 million, edging past consensus.
• £1.9 billion cost-savings programme unveiled: The three-year "Accelerate Growth" plan targets annual savings by 2029, with most funds reinvested into the late-stage pipeline.
• Shares hit a three-month high: GSK stock surged as much as 6% in London following the release, reflecting broad investor approval of the results and strategic update.

Earnings Context and Why It Matters

GSK's second-quarter report carried extra weight because it coincided with the company's "Accelerate Growth" strategy event, where CEO Luke Miels laid out the long-term vision for the drugmaker. Investors have been closely monitoring GSK's transition from a diversified pharmaceutical company into a focused biopharma player centered on specialty medicines and vaccines. The quarter also arrived against the backdrop of a looming patent cliff: dolutegravir, the backbone of GSK's HIV franchise, begins losing US patent protection in 2028. How well the company can offset that revenue erosion through pipeline acceleration and margin discipline is the central question for shareholders, making this quarter's results—and the accompanying restructuring announcement—especially significant.

Reported Results

GSK reported second-quarter 2026 turnover of £8.41 billion, a 5% increase at constant exchange rates, surpassing the company-compiled consensus of £8.24 billion. Core operating profit came in at £2.80 billion, comfortably above the £2.68 billion consensus, while core EPS of 50.5 pence beat the 47.1 pence estimate by approximately 7%.

Specialty Medicines was the standout performer, generating £3.8 billion in sales—up 14% year-on-year. Within the division, Respiratory, Immunology & Inflammation grew 19%, Oncology advanced 17%, and HIV rose 10%. The long-acting injectable HIV treatments Cabenuva and Apretude posted increases of 33% and 39%, respectively, while oncology assets Jemperli and Blenrep also delivered strong double-digit growth.

Vaccines revenue climbed 8% to £2.3 billion. Shingrix, the shingles vaccine, generated £888 million, slightly ahead of the consensus estimate of £867.8 million. Arexvy, the respiratory syncytial virus (RSV) vaccine, more than doubled its sales compared to the prior-year period. Meningitis vaccine sales rose 21%.

General Medicines remained the weak spot, with sales declining 9% to £2.3 billion, missing the £2.42 billion consensus. Trelegy, the respiratory inhaler, saw revenue dip 7%, reflecting ongoing pressures from generic competition and pricing headwinds in mature markets.

On a statutory (reported) basis, total operating profit fell 75%, weighed down by a £1.3 billion impairment charge tied primarily to camlipixant, the investigational chronic cough treatment that failed to meet endpoints in late-stage trials. GSK declared a second-quarter dividend of 17 pence per share and indicated a 70 pence full-year payout is expected.

Management reaffirmed full-year 2026 guidance, now expecting turnover growth in the upper half of the 3% to 5% range and core operating profit growth in the upper half of the 7% to 9% range. Core EPS growth is forecast in the lower half of that 7% to 9% range, reflecting additional interest expense following the Nuvalent acquisition.

AI Screener

Investors looking to identify opportunities in the pharmaceutical sector can turn to Tickeron's AI Screener, an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. The platform allows users to scan thousands of stocks and ETFs using customizable filters such as industry classification, market capitalization, technical indicators, price patterns, and performance metrics. Whether screening for breakout candidates, trending pharmaceutical names, or undervalued large-cap healthcare stocks, the AI Screener is designed to surface trade ideas and market opportunities far more efficiently than manual screening. Explore the AI Screener to see how data-driven filtering can sharpen your market research.

Market Reaction and Investor Sentiment

GSK shares jumped as much as 6% in London trading on Tuesday, reaching 2,080 pence—their highest level since mid-April—before settling to a gain of roughly 3% to 4% by midday. In New York, American Depositary Shares (ADSs) rose approximately 3.35% in premarket trading to around $53.72.

The positive reaction reflected more than just the headline beat. Investors appeared to welcome the "Accelerate Growth" cost-savings programme, which analysts at Jefferies described as "surprisingly strong"—roughly double what the market had anticipated. The plan signals that management is serious about protecting margins through the patent cliff while simultaneously funding an ambitious pipeline expansion. The announcement that GSK now expects more than 20 Phase 3 trial starts in 2026, double its previous target of around 10, also reinforced confidence in the company's ability to replenish its portfolio with high-value assets.

Forward Outlook and Key Factors to Monitor

The earnings beat and strategic reset give GSK a stronger near-term narrative, but several factors will determine whether the momentum can be sustained.

First, execution on the cost-savings programme will be closely watched. The £1.9 billion annual savings target by 2029 comes with a £2.4 billion total price tag, most of which will be recognised in 2026 and 2027. Investors will want to see early evidence that the restructuring—which includes relocating the flagship R&D (research and development) centre from Stevenage to Cambridge and undisclosed job cuts—is proceeding on schedule and within budget without disrupting core operations.

Second, the pipeline acceleration must deliver. With more than 20 Phase 3 trials now planned across 18 indications spanning oncology, respiratory, hepatology, and vaccines, the next 12 to 18 months represent a critical readout period. Positive data from these trials would meaningfully de-risk the post-dolutegravir revenue outlook. Conversely, any high-profile failures could raise difficult questions about capital allocation.

Third, the trajectory of General Medicines remains a drag that cannot be ignored. The 9% decline in the quarter underscores that the erosion in legacy products is real and ongoing. How effectively the Specialty Medicines and Vaccines divisions can compensate—and whether the margin uplift from a better product mix proves durable—will be key to meeting the company's 2031 sales target of more than £40 billion.

Finally, the macro environment for pharmaceutical stocks remains relevant. The sector has benefited from defensive rotation in recent months, and GSK's roughly 6% year-to-date gain, while trailing the broader S&P 500, reflects steady rather than exuberant investor sentiment. The company's dividend yield of approximately 3.4% and a free cash flow yield of around 8% continue to offer a measure of downside support, but meaningful stock appreciation from here likely hinges on pipeline catalysts and evidence that the cost-savings programme is translating into improved operating leverage.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations